Moderna announced this Thursday that it has requested the Food and Drug Administration (FDA) for authorization for the emergency use of its COVID-19 vaccine in adolescents between 12 to 17 years old.
If approved by the FDA, it would likely dramatically increase the number of shots available to middle and high school students for the next school year.
This week, the Moderna company also requested authorization from the European Union and Canada, and has announced its intention to do so in other countries, ensuring “high effectiveness in preventing covid-19 and infection with SARS-CoV-2” in this group of age.
“We are encouraged that Moderna’s covid-19 vaccine was very effective in preventing covid-19 and SARS-CoV-2 infections in adolescents,” said the firm’s CEO, Stéphane Bancel, in a statement.
Moderna reiterated that the request is based on a study conducted with 3,700 people in the United States, which showed that the product is safe and 100% effective for adolescents, according to data it released in May.
Regarding side effects, Moderna cited situations similar to those registered with adults, such as arm pain, fatigue and headaches.
So far, the American pharmaceutical vaccine is used only in those over 18 years of age and if approved, it would become the second to receive the green light for use with adolescents, after that of Pfizer and BioNTech, already authorized in the United States, Europe and Canada.
Photo Source: AP